Scientists cause human cancer cell death by inhibiting telomerase

December 06, 1999

DALLAS -December 7, 1999 - Scientists at UT Southwestern Medical Center at Dallas caused the death of human cancer cells by inhibiting telomerase - the enzyme capable of immortalizing human cells. They developed small synthetic inhibitors against telomerase that when introduced into human cancer cells caused progressive telomere shortening and eventually cell death.

The study, published in today's issue of the Proceedings of the National Academy of Sciences, validates telomerase as a target for anti-cancer drug therapy.

Dr. David Corey, Dr. Jerry Shay and collaborators designed nucleotide sequence inhibitors to interact with complementary sequences in the telomerase gene, thereby preventing its activity. These inhibitors led to the progressive shortening of telomeres in human breast and prostate cancer-cell lines grown in the laboratory. The researchers also showed that if the inhibitor was withdrawn, the telomeres regained their initial lengths.

"The use of anti-telomerase synthetic inhibitors should open up a new class of therapeutic cancer drugs that will have a powerful role in cancer therapy," said Shay, professor of cell biology. "They should prevent the recovery of residual cancer cells following conventional therapy and thus make them more susceptible to attack by the immune system or killing by existing therapeutic agents."

Telomerase activity is widely recognized as a marker of cancer cells, and its activity has been correlated with tumor aggressiveness in a number of studies. While most normal cells have finite life spans and do not contain telomerase, more than 90 percent of cancer cells, which divide indefinitely, contain telomerase.

Previous work (Science 279:349-52, 1998) by Shay; Dr. Woodring Wright, professor of cell biology; other UT Southwestern co-workers; and Geron Corp. colleagues proved that telomerase was sufficient to immortalize normal human cells grown in the laboratory and that progressive shortening of telomeres - specific short pieces of deoxyribonucleic acid (DNA) that telomerase adds back to the ends of chromosomes - is the biological clock that governs how many times a cell divides.

Because telomerase has an essential ribonucleic acid (RNA) component that acts as a template for adding back telomeres to the ends of chromosomes, Corey and colleagues designed short pieces of RNA and DNA to bind to the telomerase RNA template and block the enzyme's activity. These synthetic inhibitors belong to a family of molecules already being tested in clinical trials for other diseases.

"Using the synthetic inhibitors we designed, we are confident that the effects we observed are due to the inhibition of telomerase," said Corey, associate professor of pharmacology and biochemistry. "This opens the door to the next step - rational and well-controlled animal studies."

In theory telomerase inhibition should prevent the addition of new telomeres but not cause immediate cell death. With each successive cell division, the telomere length should decrease - as seen in normal human cells that have no telomerase - until due to shortened telomere length, the cells die. The time between addition of the inhibitor and cell death should depend on the initial telomere length- the shorter the telomere length, the sooner cell-growth inhibition is achieved.

"In the experiment, which was carried out for over 100 days, no cells survived the anti-telomerase treatment. In most current cancer therapies, there are often some tumor cells that survive the initial treatment, and this can often lead to cancer relapses," Shay said. "Since no cells survived in the study, this indicates that alternative mechanisms to maintain telomere length were not easily activated."

Other UT Southwestern investigators participating in the study were lead co- authors cell biology postdoctoral fellow Dr. Brittney-Shea Herbert and molecular biophysics graduate student Anne Pitts; research technician Scott Baker and research associate Susan Hamilton, both of the Howard Hughes Medical Institute; and Wright.

Grants from the Robert A. Welch Foundation, the National Institutes of Health, the National Cancer Institute, the Susan G. Komen Breast Cancer Foundation and Geron helped fund the study.

UT Southwestern Medical Center

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to